Researchers have harnessed the power of artificial intelligence to tackle one of the most complex challenges in immunology: predicting how T cells recognize and respond to specific peptide antigens.

A new AI tool that models how variations in peptides change T cell receptor binding could help design immunotherapies with fewer off-target effects. Protein complexes that adorn the surface of T cells ...

Zeaxanthin, best known for eye health, has been found to boost the tumor-killing power of T cells. Researchers showed it ...

Bristol Myers Squibb has agreed to buy privately held biotechnology company Orbital Therapeutics for $1.5 billion in cash in a deal that bolsters the drugmaker's cell-therapy portfolio.

Recent research indicates that the spatial architecture of membrane proteins is crucial for regulating T-cell signaling and activation. 3-5 In the context of CAR T cells, the nanoscale localization ...

Capturing Unicorns: Targeting Cancers With TP53 Mutations, RAS Alterations Beyond G12C, and MTAP Loss—No Target Is Out of the Realm of Possibility Modified, autologous T-cell immunotherapies have been ...

Cemacabtagene ansegedleucel, an allogeneic chimeric antigen receptor (CAR) T-cell therapy, is being investigated in relapsed/refractory large B-cell lymphoma. The investigational allogeneic chimeric ...